NBTXR3 First in Class Radioenhancer
Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.
Only one administration
Fits into existing standard of care:
One product addressing areas of high unmet medical needs.
See moreRecent Press Releases
Nanobiotix to Announce Full Year 2021 Financial Results on March 30, 2022
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
Nanobiotix Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 with Anti-PD-1 and Anti-CTLA-4
ALL NANOBIOTIX PRESS RELEASES
Events
Meet Nanobiotix International events and conferences
JOIN US
“Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”
Anne-Juliette Hermant
Chief People Officer